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THE polymorphonuclear  neutrophils  (PMN)  possess
sufficient potential to affect both immune response
and  inflammation,  however  it  has  not  been  yet
described in the course of multiple sclerosis (MS). We
have  studied  binding  of  fluorescein  isothiocyanate
(FITC)-  stained  TNF-a by  PMN,  the  expression  of
CD11a, CD11b, and CD18 molecules of b 2-integrines
and the expression of CD10 (neutral endopeptidase-
NEP) and of CD13 (aminopeptidase N; APN) antigens
on PMN in three different groups of MS patients. The
control group included neurological patients (OND)
with noninflammatory diseases. The obtained results
have proved that during MS exacerbation and in the
course of chronic progressive MS, PMN reveal several
forms of preactivation, including significantly higher
stained-TNF-a binding,  higher expression of  CD11b
and  CD18,  as  well  as  CD10  and  CD13  antigens,  in
comparison with MS remission or OND. We suggest
that the increased expression of these molecules on
PMN of MS patients in exacerbation of the disease and
to a lower degree in the course of CP-MS is a result of
PMN  priming,  and  directly  prove  the  PMN  involve-
ment in the disease pathogenesis.
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Introduction
Multiple sclerosis (MS) is a disease in which multifocal
inflammation and damage of the blood–brain barrier
and  myelin  sheath  are  salient  pathologic  features.
Overwhelming  evidence  demonstrates  that  MS  is  a
predominantly  T-cell  and  monocyte/macrophage-
mediated  autoimmune  disorder.
1,2 Polymorphonu-
clear neutrophils (PMN) have not been considered as a
cell population participating in it.
3 PMN can however
express immunoregulatory abilities, that has not been
yet described in the course of MS. Activated in vitro
PMN produce a number of immune mediators includ-
ing cytokines like IL-1b , IL-4, IL-6, IL-8, IL-10, IL-12,
TNF, TGF-b 1.
4,5 Therefore the regulatory functions of
these cells may be postulated in the course of MS.
PMN in the peripheral blood (PB) of MS patients
can be primed mainly by inflammatory cytokines like
IL-1,  INF-g ,  or  by TNF-a secreted  by  mononuclear
cells. Hypothetically PMN priming or activation in PB
of  MS  patients  may  depend  also  on  complement
(especially C5a) immunological complexes, or certain
metabolites of the arachidonic acid (LTB4, PAF).
Priming results in the enhanced expression on PMN
of receptors for chemokines and other chemotactic
peptides,
6 priming also enhances the expression  of
CD11b/CD18 molecules on PMN cell surface
7,8 which
results in  the  indirect  activation  of PMN.
9,10 In  the
presented paper we have suggested that PMN priming
can be observed in MS patients peripheral blood.
Patients and methods
Patients (34 total; 19 women and 15 men, aged 22–56
years) were selected with a clinically definitive diag-
nosis of MS
11 and with Kurtzke Expanded Disability
Status  Scale
12 scores  5  or  fewer  and  categorized  as
having the relapsing-remitting MS (RR-MS) course for at
least 5 years but currently in remission (REM) (n=13),
as having either secondary CP-MS for at least 2 years
(n=13) or RR-MS and currently experiencing clinical
exacerbation  (REL) of the disease (n=12).  Exacerba-
tions were defined as the appearance of new symptoms
or significant worsening of the old ones, attributable to
MS, for at least 24 hours without any fever.
The control group consisted of patients with other
neurological diseases (OND) (14  total;  nine women
and  five men, aged from 24 to  37 years), including
those with vasomotor headache (n=8) and ischialgia
(n=6).
Sample collection
The studies were performed on PMN of the periph-
eral venous blood, collected into heparin-containing
tubes (10 U/ml).
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The  synthesis  and  biological  analysis  of  the  TNF
molecules  were  performed  at  the  Department  of
Bioorganic  Chemistry,  L´ od´ z,  Poland  (Patent  No.
168858). TNF staining was done with  FITC (Serva),
according to Shirakawa et al.
13 100 mg of FITC and
100 m l  of  0.2 M  carbonate  buffer  (pH  =  9.2)  were
added to 400 m g of TNF , diluted in 400 m l of PBS and
then, incubated for 6 h at 4°C. The labelled TNF was
separated  from  the  non-labelled  with  FITC  by  gel
filtration on a 3.5 cm
3 column, filled with Sephadex
G-25. TNF labelled FITC (TNF-FITC) was sterilized by
filtration, using a  0.22m m filter and  then, stored at
4°C. The staining efficiency was measured, taking into
account  the  absorbency  at  280nm,  in  comparison
with  the  absorbency  at  495 nm. The  investigations
were performed within 10 days after the TNF labelling
due to relatively low stability of the labelling.
Evaluation of TNF-FITC binding to PMN
One hundred m l of the whole blood was incubated
with TNF-FITC at the concentration of 1000 ng/ml for
2 h at 4°C. The erythrocytes were lysed, using 1 ml of
FACS Lysing Solution (Becton Dickinson) for 15 min at
room temperature. Cells were centrifuged for 5min at
400  3 g,  then  washed  with  3 ml  of  PBS  and
suspended in 100 m l of PBS. The fluorescence inten-
sity  of PMN  was  measured  using  a  flow  cytometry
FACScan  (Becton  Dickinson)  and  Lysis  II  software.
Each  measurement  was  repeated  four  times  and
presented  here  as  a  mean  fluorescence  intensity
(MFI). Specificity of the binding of TNF-FITC to PMN
was evaluated in blocking experiment by preincuba-
tion of the PMN with non-stained TNF in excess for
45 min before TNF-FITC binding (Fig. 1).
Evaluation of the expression of CD11a, CD11b
and CD18 molecules of LFA-1 and Mac-1
intregine and CD10 and CD13 Ag of neutral
endopeptidase (NEP) and aminopeptidase N
(APN) on PMN
The  determination  of  molecule  expressions  on  the
surface of PMN was performed in the whole blood.
Techniques,  generally  used  for  immunofluorescent
labelling  of  the  cells  in  whole  blood  collected  on
heparin, were applied. One hundred m l of blood was
mixed  and  incubated  at  room  temperature  with
appropriate  quantities  of  monoclonal  antibodies,
provided  by  Dako  (Denmark).  CD11a,  CD11b  and
CD18  antibodies  were  used. A  double-step  staining
procedure was used for the evaluation of CD10 and
CD13 Ag  expression.  Mouse  immunoglobulins  anti-
CD10  and  CD13  (Dako)  were  used  as  a  first  step.
Rabbit anti-mouse IgG polyclonal immunoglobulins G
stained with R-phycoerythrin were used as a second-
ary  antibody.  Mouse  IgG2a,  stained  with  RPE,  was
used as a negative control. Erythrocytes were elimi-
nated  by  an  addition  of  lysing  solution  (Becton
Dickinson) into the blood samples. After a short time
of incubation and rinsing, the cells were suspended in
physiological  buffered  saline  (PBS).  FACscan  flow
cytometer with a  488 nm argon  laser (Becton Dick-
inson)  and  Lysis  II  software were  used. The  results
were expressed as the values of MFI of the labelled
surface antigens.
Results
The MFI of the PMN incubated with FITC-TNF was
highest  in  the  group  with  exacerbation  of  RR-MS
(REL) (Table 1) and the value was significantly higher
(P<0.01)  compared  with  the  other  groups  of  MS
patients and to OND. In the course of CP-MS and in
MS  remission  (REM)  the  tested  values  were  in  the
range observed in the control group (OND).
Expression  of  CD10,  CD13 Ag  and  CD11b/CD18
molecules on PMN was significantly increased in REL
(P<0.05 and P<0.01) compared with that examined in
CP-MS, REM and OND (Table 1). CD11a expression on
PMN in REL was the same as in CP-MS patients and in
OND.  In  the  course  of  CP-MS  only  expressions  of
CD11b  and  CD18  but  not  CD10  and  CD13  were
significantly  increased  (P<0.01  and  P<0.05)  com-
pared with OND. Expressions of CD11a, CD11b and
CD10  were  markedly  diminished  (P<0.01  and
P<0.05) during remission of MS compared with the
controls (Table 1).
Discussion
It has been proved in previous studies that there is a
more  intensive  inflammatory  response  in  acute
exacerbations of RR-MS patients than in the course of
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FIG. 1. Flow cytometric analysis of the TNF-FITC binding to
PMN.  Non-stained  TNF  added  in  1000  times  excess  (C),
significantly diminished MIF corresponding  to nonspecific
binding of control IgG-FITC (A) and IgG-FITC + non-stained
TNF (B). The result (D) proves specificity of the TNF-FITC
binding to TNF-R on PMN.CP-MS.
2 The  obtained  data  suggest  that  relapsing-
remitting MS follows cycles of immunological activa-
tion as a result of Th-1 response (exacerbation), which
is  then  followed  by  a  suppressor  response  that
downregulates inflammation (remission).
1,2 In CP-MS
there is continuous low-grade inflammation with no
obvious exacerbations or remissions.
The  involvement  of TNF  in  immunopathological
processes  in  MS  has  already  been  known  for  quite
some  time.
14 This  cytokine  is also  one  of the most
potent  priming  factors  for  PMN  in  vitro.
7,15 We
suggest  that  serum  TNF  of  patients  with  acute
exacerbations  of  RR-MS  or  in  lower  degree  in  the
course of CP-MS can be the main priming factor of
PMN.
TNF in vitro stimulates the expression of many of
the  PMN  surface  molecules.  Simultaneously  TNF
stimulates its own  receptors expression (TNF-R) on
PMN.
16 This has been confirmed in our study as the
increased TNF binding to PMN in the course of acute
exacerbations  of  MS.  We  have  observed  also  the
significant  increase  of  the  CD10,  CD13  Ag  and
CD11b/CD18  molecule  expression  on  PMN  of  MS
patients, mainly in the course of exacerbation com-
pared with MS remission and with OND groups. This
may be a sign of priming of PMN in MS exacerbation
and to a lower degree in the course of CP-MS.
Podikoglou  et  al.
3 have  shown  that  the  typical
functions of PMN, like adherence, chemotaxis, pha-
gocytosis  or  bactericidal  action  have  been  signifi-
cantly  diminished  in  PB  of  MS  patients. The  results
that we have obtained in our study correspond with
Goto  et  al..
17 In  some  earlier  observations Aoki  et
al.
18 and  Guarnieri  et  al.
19 have  shown  that  the
increased intracellular neutral proteinase and medul-
lasine  concentrations  can  be  the  symptom  of  PMN
activation in the blood of patients with acute exacer-
bation  of  MS.
PMN  contain  large  amounts  of  proteinases,  like
NEP and APN, in their intracellular granules.
20,21 The
increased expression on in vitro stimulated PMN is a
result of rapid translocation of an intracellular pool to
the  cell  surface.
22,23 The  increased  expression  of
CD11b/CD18–Mac-1 molecules probably results from
their rapid shift from internal granules to the surface
of primed PMN. Such process has not been observed
in CD11a/CD18 molecules of LFA-1 integrine expres-
sion of in vitro primed PMN.
24,25 In our studies we
have not noticed the increased expression of CD11a
molecule on PMN of MS patients with acute exacerba-
tions or in the course of CP-MS. In our opinion, these
can suggest PMN priming in patients with active MS.
Activated  PMN  can  produce  oxygen  and  nitrogen
species,  some  matrix  degrading  metalloproteinases
and  some  cytokines.
5,26 Priming  is  a  preliminary
event before receptor-induced stimulation of PMN. It
is  then  a  sign  of  these  cells’  hyperreactivity.  PMN
priming features observed in the PB of patients with
active MS suggest that these cells may participate in
the MS immunopathology.
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